A Phase 1, Open Label, Ascending Dose Study to Evaluate the Safety of BBC1501 Administered by Intravitreal Injection for Neovascular Age-Related Macular Degeneration (nAMD)
Latest Information Update: 17 Jul 2025
At a glance
- Drugs BBRP 11001 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors BenoBio
Most Recent Events
- 08 Jul 2025 Planned End Date changed from 1 Oct 2025 to 1 Mar 2026.
- 08 Jul 2025 Planned primary completion date changed from 1 May 2025 to 1 Dec 2025.
- 08 Jul 2025 Status changed from not yet recruiting to recruiting.